Loading...
XNAS
AKYA
Market cap64mUSD
Jul 07, Last price  
1.29USD
1D
-5.15%
1Q
25.24%
IPO
-94.38%
Name

Akoya Biosciences Inc

Chart & Performance

D1W1MN
P/E
P/S
0.79
EPS
Div Yield, %
Shrs. gr., 5y
5.90%
Rev. gr., 5y
14.10%
Revenues
82m
-15.48%
42,236,00042,443,00054,917,00074,859,00096,633,00081,672,000
Net income
-55m
L-12.57%
-14,751,000-16,706,000-42,935,000-70,641,000-63,323,000-55,365,000
CFO
-44m
L-13.35%
-13,776,000-6,843,000-36,068,000-53,496,000-50,899,000-44,103,000
Earnings
Aug 04, 2025

Profile

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
IPO date
Apr 16, 2021
Employees
369
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
81,672
-15.48%
96,633
29.09%
74,859
36.31%
Cost of revenue
53,539
62,217
54,680
Unusual Expense (Income)
NOPBT
28,133
34,416
20,179
NOPBT Margin
34.45%
35.62%
26.96%
Operating Taxes
146
40
123
Tax Rate
0.52%
0.12%
0.61%
NOPAT
27,987
34,376
20,056
Net income
(55,365)
-12.57%
(63,323)
-10.36%
(70,641)
64.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
47,967
447
BB yield
-22.12%
-0.12%
Debt
Debt current
3,283
6,896
3,629
Long-term debt
12,645
92,710
84,662
Deferred revenue
3,193
2,114
Other long-term liabilities
83,156
5,765
6,039
Net debt
(19,112)
16,481
6,770
Cash flow
Cash from operating activities
(44,103)
(50,899)
(53,496)
CAPEX
(2,456)
(3,653)
(7,360)
Cash from investing activities
(24,051)
3,347
(14,079)
Cash from financing activities
(3,205)
56,844
28,726
FCF
30,345
25,953
5,419
Balance
Cash
35,040
83,125
81,218
Long term investments
303
Excess cash
30,956
78,293
77,778
Stockholders' equity
(285,427)
(230,069)
(166,752)
Invested Capital
384,142
381,951
309,270
ROIC
7.31%
9.95%
7.05%
ROCE
28.46%
22.65%
14.15%
EV
Common stock shares outstanding
49,419
44,435
37,747
Price
2.29
-53.07%
4.88
-49.01%
9.57
-37.49%
Market cap
113,168
-47.81%
216,841
-39.97%
361,238
-36.95%
EV
94,056
233,322
368,008
EBITDA
35,787
43,306
27,328
EV/EBITDA
2.63
5.39
13.47
Interest
10,429
8,761
4,554
Interest/NOPBT
37.07%
25.46%
22.57%